abstract: This Danish cross-sectional study (n   =   20,905) showed that @entity1 aged 65-81  years generally underestimated @entity174 risk compared to absolute risk estimated by the FRAX   algorithm. Significant association was found between risk factors (e.g., previous @entity174 , @entity173 , and self-rated heath) and self-perceived @entity174 risk. Although @entity1 recognized the importance of some @entity174 risk factors, a number of significant risk factors appeared to be less well known. INTRODUCTION: The aim of this study is to investigate @entity1 's self-perceived @entity174 risk and potential factors associated with this and to compare self-perceived risk with absolute @entity174 risk estimated by FRAX   in @entity1 aged 65-80  years. METHODS: Data from 20,905 questionnaires from the @entity170 study were analyzed. The questionnaire included 25 items on @entity170 , risk factors for @entity174 , and self-perceived risk of @entity174 and enabled calculation of absolute @entity174 risk by FRAX  . Data were analyzed using bivariate tests and regression models. RESULTS: @entity1 generally underestimated their @entity174 risk compared to absolute risk estimated by FRAX  . @entity1 with risk factors for facture estimated their @entity174 risk significantly higher than their peers. No correlation between self-perceived risk and absolute risk was found. The ordered logistic regression model showed a significant association between high self-perceived @entity174 risk and previous @entity174 , @entity173 , falls, self-rated heath, conditions related to secondary @entity170 , and inability to do housework. CONCLUSIONS: These @entity1 aged 65-81  years underestimated their risk of @entity174 . However, they did seem to have an understanding of the importance of some risk factors such as previous @entity174 , @entity173 and falls. Risk communication is a key element in @entity174 prevention and should have greater focus on less well-known risk factors. Furthermore, it is important to acknowledge that risk perception is not based solely on potential risk factors but is also affected by experiences from everyday life to personal history.

title: Self-perceived facture risk: factors underlying @entity1 's perception of risk for osteoporotic fractures: the @entity170 ( XXXX ).

entities_list: @entity173 :: ('MESH:D006620', 'Disease') :: ['parental hip fracture']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['ROSE', 'osteoporosis']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fragility fracture', 'fracture']

answer: @entity170 :: (MESH:D010024,Disease) :: ['ROSE']


abstract: UNASSIGNED: Standard treatment for @entity1422 , a severe @entity74 , is platelet transfusion. Recombinant factor VIIa is reported to be effective in @entity1422 with platelet antibodies and/or refractoriness to platelet transfusions. We aimed to evaluate recombinant factor VIIa effectiveness and safety for the treatment and prevention of surgical @entity548 in @entity1 , with or without platelet antibodies and/or refractoriness, using data from the Glanzmann @entity1422 Registry, an international, multicenter, observational, post-marketing study of rFVIIa. Between 2007 and 2011, 96 @entity1 were treated for 206 surgical procedures (minor 169, major 37). History of platelet antibodies was present in 43 @entity1 , refractoriness in 23, antibodies+refractoriness in 17, while 47 had no confirmed antibodies/refractoriness. Treatments analyzed included antifibrinolytics, recombinant factor VIIa, recombinant factor VIIa+antifibrinolytics, platelets +/-antifibrinolytics and recombinant factor VIIa+platelets+/-antifibrinolytics. The most frequent treatment for minor procedures was recombinant factor VIIa+antifibrinolytics (n=65), and for major procedures, recombinant factor VIIa+platelets+/-antifibrinolytics (n=13). In patients without antibodies/refractoriness, recombinant factor VIIa, either alone or with antifibrinolytics, and platelets+/-antifibrinolytics were rated 100% effective for minor and major procedures. The effectiveness of treatment for minor procedures in patients with antibodies and refractoriness was 88.9% for recombinant factor VIIa, 100% for recombinant factor VIIa+antifibrinolytics, 66.7% for platelets+/-antifibrinolytics and 100% for recombinant factor VIIa+platelets+/-antifibrinolytics. One of four adverse events reported for surgery was considered recombinant factor VIIa-treatment related (non-fatal @entity1031 event in an adult female receiving recombinant factor VIIa+platelets+antifibrinolytics). For all @entity1 , regardless of platelet antibody or refractoriness status, recombinant factor VIIa, administered with or without platelets (and +/- antifibrinolytics), provided effective hemostasis with a low frequency of adverse events in surgical procedures in @entity1422 @entity1 . ClinicalTrials.gov Identifier: NCT01476423.

title: The international prospective Glanzmann XXXX Registry: treatment and outcomes in surgical intervention.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['inherited bleeding disorder']

entities_list: @entity1422 :: ('MESH:D013915', 'Disease') :: ['Thrombasthenia', 'Glanzmann thrombasthenia']

answer: @entity1422 :: (MESH:D013915,Disease) :: ['Thrombasthenia']


abstract: A case of @entity1769 -induced @entity3326 with cerebrospinal fluid (CSF) @entity8193 was reported. A 44-year-old Japanese @entity1 noted tarry stool on July 2, 1988 and was treated with @entity1769 and @entity4444 for @entity390 and @entity391 . @entity5774 was also administered for insomnia at 3:10 am and she became comatose with @entity2003 at 3:40-4:30 am on July 3. @entity591 and high fever (39.5 degrees C) were evident at 8:00 am on July 4. She was transferred to the Kyushu University Hospital. On admission, serum @entity908 kinase was elevated to 1640 IU/1; MM fraction was 100%. She was diagnosed as @entity5 . Cerebrospinal fluid was normocellular with protein 38 mg/dl and @entity413 122 mg/dl. Cerebrospinal fluid @entity880 increased markedly to 3.43 mmol/l, CSF pH was 7.264, HCO3- 14.4 mEq/l, indicating CSF @entity520 . She became afebrile after the 10th hospital day, and gradually but completely recovered within a month. She was discharged on August 16, 1988. The anti-dopaminergic activity of @entity1769 was considered to be primarily responsible for the development of @entity5 in this case. Cerebrospinal fluid @entity8193 seemed to reflect @entity590 or @entity5 induced @entity9555 .

title: [A case of @entity1769 -induced XXXX with cerebrospinal fluid @entity8193 ].

entities_list: @entity3326 :: ('MESH:D009459', 'Disease') :: ['neuroleptic malignant syndrome']

entities_list: @entity4444 :: ('MESH:D002927', 'Chemical') :: ['cimetidine']

entities_list: @entity2003 :: ('MESH:D009127', 'Disease') :: ['muscle rigidity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant syndrome']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity9555 :: ('MESH:D001928', 'Disease') :: ['derangement of the brain metabolism']

entities_list: @entity5774 :: ('MESH:D006919', 'Chemical') :: ['Hydroxyzine pamoate']

entities_list: @entity8193 :: ('MESH:D000140', 'Disease') :: ['lactic acidosis']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['Tachycardia']

entities_list: @entity520 :: ('MESH:D000138', 'Disease') :: ['metabolic acidosis']

entities_list: @entity1769 :: ('MESH:D008787', 'Chemical') :: ['metoclopramide']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity590 :: ('MESH:D008305', 'Disease') :: ['hyperpyrexia']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity3326 :: (MESH:D009459,Disease) :: ['neuroleptic malignant syndrome']


abstract: Degeneration of spinal motoneurons has been well documented in @entity746 ( @entity746 ), but the evolution of central @entity4681 is largely unknown. It has been suggested that @entity2227 -mediated neuroexcitotoxicity may be involved in the pathogenesis of @entity746 and that this may be manifest as an increase in corticomotor excitability early in the disease. Serial measurements of corticomotor threshold, @entity713 ( @entity713 ), silent period duration and the amplitude of compound muscle action potentials (CMAPs) from ulnar nerve stimulation in the right and left first dorsal interosseous muscles were made in 76 @entity1 with idiopathic @entity746 , 49 of whom were followed from presentation to death. Threshold to transcranial magnetic stimulation was determined by standard methods and @entity713 was measured using the F-wave method. Silent period was estimated during a small background contraction of the muscle. @entity1 were classified according to the region of onset and the physical signs in the hands. The region of onset was bulbar in 17 @entity1 , lower limb in 31 @entity1 and upper limb in 28 @entity1 . At presentation, 23 @entity1 had no abnormal physical signs in the hands, 25 had lower motoneuron signs only, 14 had upper motoneuron signs only and the remainder (14) had mixed upper and lower motoneuron signs in the hands. Evolution of the central conduction parameters was determined in relation to time from onset of symptoms and also as a function of normalized total disease duration in the @entity1 who had died. Corticomotor threshold and @entity713 showed no change as the disease evolved except for @entity1 with mixed signs, who had a terminal increase in threshold and prolongation of @entity713 . Silent period duration was shorter than normal early in the disease and showed progressive lengthening throughout the illness, but nevertheless remained within the normal range regardless of the region of onset. @entity13432 amplitude showed a linear decline over the course of the disease. There was therefore no evidence of a phase of increased corticomotor hyperexcitability at any stage of disease progression. The early shortening of silent period, however, probably represents a shift in the balance of excitatory and inhibitory inputs to the cortical output cells responsible for @entity2045 , and could be a reflection of degeneration of cortical interneurons. None of the measures of central motor function in @entity746 are likely to be useful for monitoring @entity1 in a clinical trial setting.

title: The natural history of central XXXX in @entity746 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity713 :: ('MESH:D054537', 'Disease') :: ['CMCT', 'central motor conduction time']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['voluntary action']

entities_list: @entity4681 :: ('MESH:D016472', 'Disease') :: ['motor abnormalities']

entities_list: @entity746 :: ('MESH:D000690', 'Disease') :: ['ALS', 'amyotrophic lateral sclerosis']

answer: @entity4681 :: (MESH:D016472,Disease) :: ['motor abnormalities']


abstract: We describe a new gene (Oogenesin) that is expressed through oogenesis and early embryogenesis in the @entity19 . De novo expression starts at 15.5 dpc (days postcoitum) in the ovary, which coincides with the start of oogenesis. The isolated cDNA was 1387 base pairs (bp) in length with a single open reading frame of 326 @entity1522 corresponding to a predicted molecular mass of 37 kDa with no significant homology to previously reported sequences. A remarkable characteristic of the gene is the presence of a @entity368 zipper structure at @entity535 positions 131-152 and a @entity368 -rich domain at positions 131-254. Northern blot analysis demonstrated that the mRNA was present only in the ovary, in which it was expressed as a single transcript of approximately 1.7 kb. In situ hybridization revealed distinct signals in the oocytes in follicles at all stages (primordial to antral follicles). Western blot analysis demonstrated that the protein is expressed from oocytes to four-cell-stage embryos and that it has a little larger size (46 kDa) than the predicted size of 37. Immunohistochemical analysis of ovary sections revealed that the protein is also expressed specifically in oocytes in follicles at all stages. Furthermore, immunostaining of preimplantation embryos revealed that the protein localizes in nuclei at the late one-cell and early two-cell stages. These results suggest that the gene has some roles in zygotic transcription of early preimplantation embryos as well as folliculogenesis and oogenesis in the @entity19 .

title: Oogenesin is a novel XXXX protein expressed in oocytes and early cleavage-stage embryos.

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity368 :: ('CHEBI:25017', 'Chemical') :: ['leucine']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: INTRODUCTION: The aim of present study is to inverstigate the association between antibody levels after vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) and subsequent serious @entity7706 in @entity309 ( @entity309 ) and @entity5145 ( @entity5145 ) @entity1 . METHODS: A cohort of 497 @entity1 ( @entity309 =248 and @entity5145 =249) received a single dose of PCV7. At vaccination, @entity1 were treated with @entity1499 ( @entity6822 ; n=85), anti- @entity5 @entity39 factor (anti- @entity2874 )   +   @entity6822 (n=169), anti- @entity2874 monotherapy (n=158) and non-steroidal anti-inflammatory drugs (NSAIDs)/analgesics (n=85). Antibody levels of serotypes 6B and 23B were analyzed before and 4 to 6 weeks after vaccination using standard enzyme-linked immunosorbent assay (ELISA). Serious @entity7706 ( @entity55 /lower respiratory tract @entity281 , @entity693 , @entity295 , @entity5414 ) occurring within 4.5 years after vaccination were identified in the Sk  ne Healthcare Register using the International Classification of Diseases, tenth revision (ICD-10) codes. The association between post-vaccination antibody levels and protection against @entity281 and determination of protective cutoff levels was explored using receiver operating characteristic (ROC) curves. Predictors of @entity281 were studied using regression analyses. RESULTS: Eighteen @entity281 were registered in 15 @entity1 before vaccination and 27 @entity281 in 23 @entity1 after vaccination. @entity1 with serious @entity281 after vaccination had significantly lower post-vaccination antibody titres for both 6B (P=0.04) and 23 F (P=0.04). Post-vaccination antibody levels of at least 1.29 mg/L and 1.01 mg/L for 6B and 23, respectively, were associated with better protection from serious @entity281 . Higher age, concomitant @entity617 but not @entity6822 or anti- @entity2874 were associated with such @entity281 . CONCLUSIONS: @entity1 with more robust antibody responses after vaccination with pneumococcal conjugate vaccine were less likely to suffer from serious @entity281 . High age and @entity617 at vaccination were associated with putative serious @entity7706 in this cohort. TRIAL REGISTRATION NUMBER: EudraCT EU 2007-006539-29 and NCT00828997 . Registered 23 January 2009.

title: The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent @entity7706 in chronic arthritis XXXX .

entities_list: @entity7706 :: ('MESH:D011008', 'Disease') :: ['pneumococcal infections']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity5414 :: ('MESH:D001170', 'Disease') :: ['septic arthritis']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections']

entities_list: @entity5145 :: ('MESH:D025242', 'Disease') :: ['spondylarthropathy', 'SpA']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: 2011 American Academy of Pediatrics guidelines recommended @entity1494 ( @entity1494 ) as the only evaluation after febrile urinary tract infection (FUTI) in @entity1 aged 2-24 months. We determined the sensitivity, specificity, and false negative rate of @entity1494 to identify DMSA-detected @entity8 in this age group as well as in older @entity1 . METHODS: Consecutive @entity1 referred to pediatric urology with a history of FUTI underwent DMSA >= 3 months after FUTI. Abnormal @entity1494 was defined as: Society of Fetal Urology @entity3041 grades I-IV; hydroureter >= 7  mm; @entity8 as focal parenchymal thinning; and/or size discrepancy >= 1  cm between kidneys. Abnormal DMSA was presence of any focal @entity5099 and/or split renal function <44%. We calculated sensitivity, specificity, positive and negative predictive values, and false negative rates of @entity1494 compared to DMSA. RESULTS: 618 @entity1 (79% female), median age 3.4 years, were referred for FUTIs. Of the 512 (83%) with normal @entity1494 , 99 (19%) had abnormal DMSA. @entity1 with normal @entity1494 after their first FUTI had abnormal DMSA in 15/151 (10%) aged  <=24 months and 23/119 (19%) aged >24 months. @entity1494 had poor sensitivity (34%) and low positive predictive value (47%) to identify @entity1 with @entity8 . 99/149 (66%) @entity1 with @entity8 on DMSA had normal @entity1494 . CONCLUSION: After FUTI, 66% of @entity1 with @entity8 found by DMSA scintigraphy had a normal @entity1494 . Since abnormal DMSA may correlate with increased risk for @entity3025 , recurrent FUTI and @entity8 , our data suggest @entity1494 alone will fail to detect a significant proportion of @entity1 at risk. The data suggest that imaging after FUTI should include acute @entity1494 and delayed DMSA, reserving VCUG for @entity1 with abnormal DMSA and/or recurrent FUTI.

title: @entity8 detected by DMSA, despite normal renal ultrasound, in XXXX with febrile UTI.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children', 'infants']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal scar defined', 'renal damage', 'reduced renal function and/or renal cortical defects']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['renal-bladder ultrasound', 'RBUS']

entities_list: @entity3041 :: ('MESH:D006869', 'Disease') :: ['hydronephrosis']

entities_list: @entity5099 :: ('MESH:C536778', 'Disease') :: ['uptake defects']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: Fraction of exhaled @entity842 (Feno) level is used as an aid in the diagnosis and management of chronic @entity565 . Its role in @entity697 remains to be studied. OBJECTIVE: To determine whether Feno levels are elevated in @entity1 with @entity565 exacerbations compared with baseline, and whether there is a difference in Feno levels based on PCR positive (+) (respiratory virus isolated by PCR analysis) versus PCR negative (-) (respiratory virus not isolated by PCR analysis) status. METHODS: @entity1 with a previous Feno level measurement while stable and who presented to an urgent care facility with an @entity565 exacerbation were enrolled. Feno levels, spirometry, and nasal swabs for viral PCR were obtained at the time of the exacerbation and following a course of @entity229 . Data were available on 66 @entity1 . Linear mixed models were used to regress the outcomes of interest (FEV1, FEV1/forced vital capacity, forced expiratory flow at 25% to 75% of forced vital capacity, and natural log Feno) on detected virus (yes/no), visit (baseline, exacerbation, follow-up), and the interaction between the detected virus and visit. RESULTS: Compared with baseline, higher Feno values and lower lung function were found at the time of an exacerbation. A respiratory virus was detected in 59% of the exacerbations. The interaction between PCR (+) and PCR (-) groups and visit on log Feno was marginally significant (P  = .07). There was no difference in log Feno between the PCR (+) and PCR (-) groups at baseline, while higher log Feno was found in the PCR (-) group at the time of exacerbation and following @entity229 (P  = .05 and .001, respectively). CONCLUSIONS: Higher Feno concentration in PCR (-) exacerbations suggests an eosinophilic predominance in nonviral compared with viral exacerbations.

title: The Effect of Viral Infection on Exhaled XXXX in  @entity1 with Acute Asthma Exacerbations.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['acute asthma']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

answer: @entity842 :: (MESH:D009569,Chemical) :: ['Nitric Oxide']


abstract: Effective therapy of @entity751 and @entity3052 originating from @entity2590 has remained an unresolved problem. Advanced age of the @entity1 and persistent @entity3043 make the treatment difficult. Despite large number of therapeutic options none of them is satisfactory. Recently palliative treatment with low-dose @entity3601 has been reported to have certain activity. The aim of the study was to evaluate the efficacy of low-dose @entity3601 in high-risk @entity2590 ( @entity2590 ) and @entity3052 ( @entity3052 ). Twenty three @entity1 were eligible for the study: 8 with @entity2590 and 15 with @entity3052 with @entity1141 . All of them received oral @entity3601 in a daily dose of 2 mg. Median total dose of the drug was 120 mg (40-840 mg). Ten @entity1 responded to the therapy. We observed complete remission (CR) in 4, partial remission (PR) in 3 and stabilization of the disease in 3 @entity1 . Thirteen @entity1 did not respond to the therapy. The survival time of the @entity1 from the day of diagnosis and from the beginning of the treatment with @entity3601 was longer in @entity1 responding to the therapy (median 15 and 10 months, respectively) than in non-responders (4.5 and 4 months, p=0.003 and p=0.008, respectively). Low-dose @entity3601 shows significant activity in high-risk @entity2590 and @entity3052 with @entity1141 with acceptable @entity137 .

title: Efficacy and @entity137 of low-dose @entity3601 in @entity2590 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'myelodysplastic syndromes', 'MDS']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'acute myeloid leukemia with multilineage dysplasia', 'AML']

entities_list: @entity3601 :: ('MESH:D008558', 'Chemical') :: ['melphalan']

entities_list: @entity751 :: ('MESH:D013577', 'Disease') :: ['myelodysplatic syndromes']

entities_list: @entity3043 :: ('MESH:D010198', 'Disease') :: ['pancytopenia']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['multilineage dysplasia']

answer: @entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia with multilineage dysplasia']


abstract: BACKGROUND AND AIM: Although Non-steroidal anti-inflammatory drugs reduce @entity2513 in @entity1412 ( @entity1412 ), the utility of combining chemopreventive agents in @entity1412 is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any. METHODS: The primary endpoint was % change in @entity652 count in a defined field. Secondary endpoints were @entity652 burden (weighted by @entity652 diameter) and video review of entire colon/rectal segments. Adverse event (AEs) were monitored by National @entity5 Institution @entity137 criteria. RESULTS: 112 subjects were randomised: 60 @entity1 and 52 @entity1 at a mean age of 38   years. For the 89 @entity1 who had landmark-matched polyp counts available at baseline and 6   months, the mean % change in @entity652 count over the 6   months of trial was -13.0% for CXB+DFMO and -1.0% for CXB (p=0.69). Mean % change in @entity652 burden was -40% (CXB+DFMO) vs -27% (CXB) (p=0.13). Video-based global polyp change was -0.80 for CXB+DFMO vs -0.33 for CXB (p=0.03). Fatigue was the only significant AE, worse on the CXB arm (p=0.02). CONCLUSIONS: CXB combined with DFMO yielded moderate synergy according to a video-based global assessment. No significant difference in @entity652 count, the primary endpoint, was seen between the two study arms. No evidence of DFMO-related @entity2167 was seen. There were no adverse cardiovascular outcomes in either trial arm and no significant increase in AEs in the CXB+DFMO arm of the trial. Differences in outcomes between primary and secondary endpoints may relate to sensitivity of the endpoint measures themselves. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov number N01-CN95040.

title: An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['ototoxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity1412 :: ('MESH:D011125', 'Disease') :: ['familial adenomatous polyposis', 'FAP']

entities_list: @entity2513 :: ('MESH:C563365', 'Disease') :: ['colorectal adenoma burden']

answer: @entity1412 :: (MESH:D011125,Disease) :: ['familial adenomatous polyposis']


abstract: Multimodality treatment of @entity1358 with biological response modifiers and cytoreductive surgery has produced durable responses. The timing and impact of cytoreductive surgery on the success of immunotherapy require further study. We reviewed the treatment of 62 @entity1 with @entity1358 and @entity5 in place who qualified for multimodality treatment comprising adjuvant nephrectomy and biological response modifier protocols at our institution between 1987 and 1992. Of the @entity1 37 were scheduled to undergo initial adjuvant nephrectomy followed by biological response modifier therapy. A total of 25 @entity1 underwent initial biological response modifier therapy with planned delayed adjuvant nephrectomy if a response to treatment was demonstrated. Of the 37 @entity1 undergoing initial adjuvant nephrectomy, 8 (22%) were unable to enter induction of immunotherapy because of perioperative complications (1), medical contraindications (2), @entity5 progression (4) or @entity204 (1). Three @entity1 in the initial adjuvant nephrectomy group (8%) had a partial response and the median survival in this group was 12 months (range 1 to 57). In the initial biological response modifier group 3 @entity1 (12%) with an objective response (2 complete and 1 partial) to biological response modifier therapy underwent nephrectomy. The median survival for the initial biological response modifier group was 14 months (range 1 to 48). These results add to our understanding of the impact of adjuvant nephrectomy on @entity1 with @entity1358 considered for immunotherapy protocols.

title: The impact of adjuvant nephrectomy on multimodality treatment of XXXX .

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['metastatic renal cell carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['metastatic renal cell carcinoma']


abstract: Measurements of @entity79 ( @entity79 ) are useful for the assessment of @entity174 risk in @entity170 . First prospective studies showed that quantitative ultrasound as measured at the @entity8546 also predicts future @entity173 risk, independently of @entity79 and as accurately as @entity79 . The aim of this study was to compile a reference population for a new ultrasound device that determines amplitude-dependent speed of sound (AD-SOS) through the proximal phalanges of the hand and to prove its ability to distinguish between health volunteers and @entity3604 @entity1 . In a case-control study we examined 139 healthy @entity1 aged 21-94 years and a group of 24 female @entity1 aged 69-94 years with @entity173 . In the healthy reference population additional @entity79 measurements were performed with dual-energy X-ray absorptiometry (DXA) and quantitative ultrasound measurements at the @entity8546 were carried out. In vivo precision of AD-SOS measurements through the phalanges was 0.52% CV. Simple regression analyses showed a negative correlation with age (r = -0.73, p < 0.001); modest significant correlations with @entity79 of the lumbar spine (r = 0.36, p < 0.001) and @entity79 of the femoral neck (r = 0.37, p = 0.002) as measured with DXA were shown. The comparison with another ultrasound device measuring SOS and broadband ultrasound attenuation (BUA) through the @entity8546 showed correlation with SOS (r = 0.50, p < 0.001); no significant correlation was found with BUA measurements. Furthermore a dependency of AD-SOS values in anthropometric factors such as body mass index (r = 0.37, p < 0.001), height (r = 0.40, p < 0.001) and weight (r = 0.23, p < 0.05) was shown. First study results on 24 clinically diagnosed @entity3604 @entity1 , defined as @entity1 with recent (< 1 week) pertrochanteric or @entity2249 , showed a good separation between age- and sex-matched controls and @entity3604 @entity1 (Z = -2.0 SD). Receiver operating characteristic (ROC) curves showed an area under the fitted curve of 0.83 +/- 0.06. These results are powerful for a device measuring AD-SOS through the proximal phalanges of the hand, and further prospective studies have proven the capability of phalangeal ultrasound in @entity174 risk assessment.

title: Ultrasound measurements at the proximal phalanges in healthy XXXX and @entity1 with @entity173 .

entities_list: @entity3604 :: ('MESH:D058866', 'Disease') :: ['osteoporotic']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity2249 :: ('MESH:D005265', 'Disease') :: ['femoral neck fractures']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture']

entities_list: @entity8546 :: ('MESH:C566069', 'Disease') :: ['calcaneus']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD']

entities_list: @entity173 :: ('MESH:D006620', 'Disease') :: ['recent hip fractures', 'hip fracture']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND: Revision knee arthroplasty is assumed to be even more @entity158 than primary knee arthroplasty and predominantly performed in @entity1118 @entity1 , which challenges @entity282 treatment. We hypothesized that the adductor canal block, effective for @entity158 relief after primary total knee arthroplasty, may reduce @entity158 during knee flexion (primary endpoint: at 4 h) compared with placebo after revision total knee arthroplasty. Secondary endpoints were @entity158 at rest, @entity1286 consumption and @entity1286 -related side effects. METHODS: We included @entity1 scheduled for revision knee arthroplasty in general anesthesia into this blinded, placebo-controlled, randomized trial. @entity1 were allocated to an adductor canal block via a catheter with either @entity1342 or placebo; bolus of 0.75% @entity1342 /saline, followed by infusion of 0.2% @entity1342 /saline. Clinicaltrials.gov ID: NCT01191593. RESULTS: We enrolled 36 @entity1 , of which 30 were analyzed. Mean @entity158 scores during knee flexion at 4 h (primary endpoint) were: 52    22 versus 71    25 mm (mean difference 19, 95% CI: 1 to 37, P = 0.04), @entity1342 and placebo group respectively. When calculated as area under the curve (1-8 h/7 h) @entity158 scores were 55    21 versus 69    21 mm during knee flexion (P = 0.11) and 39    18 versus 45    23 mm at rest (P = 0.43), @entity1342 and placebo group respectively. Groups were similar regarding @entity1286 consumption and @entity1286 -related side effects (P > 0.05). CONCLUSIONS: The only statistically significant difference found between groups was in the primary endpoint: @entity158 during knee flexion at 4 h. However, due to a larger than anticipated dropout rate and heterogeneous study population, the study was underpowered. TRIAL REGISTRATION: Clinicaltrials.gov NCT01191593.

title: Adductor canal block for XXXX treatment after revision knee arthroplasty: a blinded, randomized, placebo-controlled study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1342 :: ('MESH:C037663', 'Chemical') :: ['ropivacaine']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'painful']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

answer: @entity282 :: (MESH:D010149,Disease) :: ['postoperative pain']


abstract: UNASSIGNED: Comprehensive assessment of @entity71 ( @entity71 ) symptoms includes parent and teacher questionnaires. The @entity71 Rating Scale-5 was developed to incorporate changes for the Diagnostic and Statistical Manual of @entity146 (5th ed.; @entity4987 ; American Psychiatric Association, 2013). This study examined the fit of a correlated, 2-factor structure of @entity71 (i.e., @entity4987 conceptual model) and alternative models; determined whether @entity71 symptom ratings varied across teacher and @entity1 demographic characteristics; and presented normative data. Two samples were included: (a) 2,079 parents and guardians (1,131 female, 948 male) completed @entity71 symptom ratings for @entity1 (N = 2,079; 1,037 males, 1,042 females) between 5 and 17 years old (M = 10.68; SD = 3.75) and (b) 1,070 teachers (766 female, 304 male) completed @entity71 symptom ratings for students (N = 2,140; 1,070 males, 1,070 females) between 5 and 17 years old (M = 11.53; SD = 3.54) who attended kindergarten through 12th grade. The 2-factor structure was confirmed for both parent and teacher ratings and was invariant across @entity1 gender, age, informant, informant gender, and language. In general, @entity1 were higher in symptom frequency than @entity1 ; older @entity1 were rated lower than younger @entity1 , especially for @entity2915 -impulsivity; and non-Hispanic @entity1 were rated higher than Hispanic @entity1 . Teachers also rated non-Hispanic African American @entity1 higher than non-Hispanic White, Asian, and Hispanic @entity1 . Non-Hispanic White teachers provided lower @entity2915 -impulsivity ratings than non-Hispanic, African American, and Hispanic teachers. Normative data are reported separately for parent and teacher ratings by @entity1 gender and age. The merits of using the @entity71 Rating Scale-5 in a multimodal assessment protocol are discussed. (PsycINFO Database Record

title: Parent and teacher ratings of XXXX symptoms: Factor structure and normative data.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'boys', 'girls', 'child']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['Mental Disorders']

entities_list: @entity71 :: ('MESH:D001289', 'Disease') :: ['ADHD', 'attention-deficit/hyperactivity disorder']

entities_list: @entity2915 :: ('MESH:D006948', 'Disease') :: ['hyperactivity']

answer: @entity71 :: (MESH:D001289,Disease) :: ['attention-deficit/hyperactivity disorder']


abstract: UNASSIGNED: A major part of cataractogenic mutations in @entity1 aA-Crystallin (aA-Cry) occurs at @entity534 residues. While @entity534 54 is highly conserved within different species, the cataractogenic mutations @entity62930 , @entity62931 and @entity28822 have been recently identified in @entity11300 gene, encoding @entity1 aA-Cry. The detailed structural and functional aspects, stability and amyloidogenic properties of aA-Cry were determined upon the above-mentioned missense mutations, using various spectroscopic techniques, gel electrophoresis, electron microscopy, size exclusion HPLC analyses, and chaperone-like activity assay. The different mutations at Arg54 result in diverse structural alterations among mutant proteins. In addition, the mutant proteins displayed reduced thermal stability, increased amyloidogenic properties and attenuated chaperone-like activity against aggregation of y-Cry, catalase and lysozyme. The mutant proteins were also capable of forming larger oligomeric complexes with y-Cry which is the natural partner of a-Cry in the eye lenses. The most significant structural and functional damages were observed upon @entity62930 mutation which was also accompanied with increased oligomeric size distribution of the mutant protein. The cataractogenic nature of @entity62931 mutation can be explained with its detrimental effect on chaperone-like activity, conformational stability and proteolytic digestibility of the mutant protein. Also, @entity28822 aA-Cry displayed an important intrinsic propensity for @entity1520 protein cross-linking with significantly reduced chaperone-like activity against all client proteins. These mutations revealed a range of detrimental effects on the structure, stability and functional properties of aA-Cry which all together can explain the pathomechanisms underlying development of the associated @entity231 .

title: The impact of different mutations at Arg54 on structure, chaperone-like activity and oligomerization state of @entity1 aA-crystallin: The pathomechanism underlying congenital cataract-causing mutations XXXX , @entity62931 and @entity28822 .

entities_list: @entity62930 :: ('p|SUB|R|54|L', 'ProteinMutation') :: ['R54L']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['congenital cataract disorders']

entities_list: @entity28822 :: ('p|SUB|R|54|C', 'ProteinMutation') :: ['R54C']

entities_list: @entity1520 :: ('CHEBI:48343', 'Chemical') :: ['disulfide']

entities_list: @entity62931 :: ('p|SUB|R|54|P', 'ProteinMutation') :: ['R54P']

answer: @entity62930 :: (p|SUB|R|54|L,ProteinMutation) :: ['R54L']


abstract: OBJECTIVES: To determine if prenatal or recent postnatal @entity5165 (MeHg) exposure from consuming ocean fish and seafood is associated with @entity2167 in young adults. Some investigators have reported adverse associations while others have found no associations. Ocean fish is an important nutrient source for billions of @entity1 around the world. Consequently, determining if there is an adverse association with objective auditory measures is important in assessing whether a risk is present or not. Design The peripheral and central auditory function of 534 subjects in the Seychelles @entity1 Development Study (SCDS) Main Cohort was examined at age 19years. The auditory test battery included standard pure-tone audiometry, tympanometry, Auditory Brainstem Response (ABR) latencies, and both click-evoked and distortion-product @entity392 ( @entity392 ). Associations with MeHg were evaluated with multiple linear regression models, adjusting for sex, recent postnatal MeHg exposure, and @entity393 . RESULTS: @entity393 (defined as a mean pure-tone threshold of greater than 25dB) was present in 1.1% of the subjects and was not associated with prenatal or recent postnatal MeHg exposure. As expected, absolute and interwave ABR latencies were shorter for @entity1 as compared to @entity1 , as the stimulus presentation rate decreased from 69.9 to 19.9 clicks/sec and as the stimulus intensity increased from 60 to 80 dBnHL. Similarly, larger @entity392 amplitudes were elicited in @entity1 as compared to @entity1 and in the right ears as compared to the left. There was no association of prenatal MeHg exposure with @entity393 , ABR absolute and interwave latencies or @entity392 amplitudes. As recent postnatal MeHg increased, some associations were found with a few ABR absolute and interwave latencies and a few @entity392 amplitudes. However, the direction of these associations was inconsistent. As recent postnatal MeHg levels increased the wave I absolute latencies were shorter at 80 dBnHL for all 3 click rates, but the interwave I-V latency was longer for males for the 80 dBnHL 19 clicks/sec and for the III-V interwave latencies for males and females for the dBnHL 69 clicks/sec. Similarly, smaller @entity392 amplitudes were found at 1500, 2000, and 4000Hz for males while larger @entity392 amplitudes were found for females at 1500 and 2000Hz as the recent postnatal MeHg levels increased. CONCLUSIONS: No consistent associations were present in this study between prenatal MeHg exposure from consumption of oceanic fish and seafood during pregnancy and auditory functions at 19years of age. Given the level of prenatal exposure to MeHg, the number of audiologic measures tested, and the presence of the expected sex, click rate, and level dependent findings, it seems unlikely that an association was present and not detected. As recent postnatal MeHg exposure increased, a few associations with ABR latencies and @entity392 amplitudes were found. The direction of these associations was inconsistent as some showed improved performance as MeHg exposure levels increased while others showed poorer performance. The presence of the inconsistent postnatal MeHg exposure findings are intriguing and deserve further clarification.

title: Associations between Prenatal and Recent Postnatal XXXX Exposure and Auditory Function at age 19years in the Seychelles @entity1 Development Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'women', 'people', 'men']

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['auditory deficits']

entities_list: @entity392 :: ('MESH:D014012', 'Disease') :: ['Otoacoustic Emissions', 'OAE']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss', 'Bilateral hearing loss']

entities_list: @entity5165 :: ('CHEBI:30785', 'Chemical') :: ['methylmercury']

answer: @entity5165 :: (CHEBI:30785,Chemical) :: ['Methylmercury']


abstract: OBJECTIVE: To analyze clinical presentation of and paraclinical @entity66 in @entity1 with @entity14204 ( @entity14204 ). @entity1 AND METHODS: We retrospectively reviewed 24 @entity1 seen at the Mayo Clinic in Rochester, Minn, between 1985 and 2002 in whom @entity14204 was suspected. @entity1 were identified on the basis of clinical history and presence of @entity5 . Data were reviewed from magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, electroencephalography (EEG), and paraneoplastic serologic studies. RESULTS: Common manifestations were @entity73 (92%), @entity410 (58%), and @entity146 symptoms (50%); 13 @entity1 had @entity151 ; 11 had other @entity5 . Paraneoplastic neuronal autoantibodies were found in 14 (64%) of 22 @entity1 tested. Electroencephalography showed focal or generalized slowing and/or @entity302 , maximal in the temporal regions, in all 22 @entity1 tested. Magnetic resonance imaging revealed increased T2 signal involving one or both temporal lobes in 15 (83%) of 18 @entity1 . Cerebrospinal fluid test results were abnormal in 18 (78%) of 23 @entity1 tested. Clinical or radiographic evidence of extralimbic involvement was documented in 12 (55%) of 22 @entity1 . No abnormality on EEG, MRI, or CSF analysis correlated with a specific @entity5 type or with a specific paraneoplastic autoantibody. CONCLUSIONS: In @entity1 with suspected @entity14204 , EEG is invaluable for confirming @entity75 . Magnetic resonance imaging can show unequivocal involvement of temporolimbic structures and helps exclude other diagnoses. When EEG and cranial MRI are both normal, @entity14204 is unlikely. Comprehensive testing for paraneoplastic neuronal nuclear, cytoplasmic, and ion channel autoantibodies is an important part of the evaluation, but negative results do not rule out @entity14204 .

title: Clinical, magnetic resonance imaging, and electroencephalographic findings in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['test abnormalities']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignancies']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive dysfunction']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['cerebral dysfunction']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptiform activity']

entities_list: @entity151 :: ('MESH:D055752', 'Disease') :: ['small cell lung carcinoma']

entities_list: @entity14204 :: ('MESH:D020363', 'Disease') :: ['paraneoplastic limbic encephalitis', 'PLE']

answer: @entity14204 :: (MESH:D020363,Disease) :: ['paraneoplastic limbic encephalitis']


abstract: OBJECTIVE: @entity41329 analog ( @entity53753 ) is an antibiotic with antitumor properties demonstrated in preclinical and phase I studies. We conducted a phase II trial to evaluate the efficacy and @entity137 of this agent in @entity1 with advanced @entity1358 ( @entity1358 ). METHODS: Eligible @entity1 had histologically or cytologically confirmed diagnosis of @entity1358 that was either locally advanced unresectable, locally recurrent, or metastatic. @entity1 had to have measurable disease, no prior chemotherapy, life expectancy of greater than 12 weeks, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate-organ function, and be >/=18 years old. @entity1 were treated with @entity53753 at a dose of 165 mg/m(2) daily i.v. over 30-60 min for 5 days. Treatment was repeated every 21 days. Response was assessed every two courses. RESULTS: Twenty-four @entity1 were enrolled. There were sixteen males and eight females with a median age of 60.5 years (range 42-76). Nineteen were Caucasians, seventeen had prior nephrectomy, and thirteen had prior immunotherapy. The major @entity137 was myelosuppression with grade 3 and 4 @entity1398 in 38% of @entity1 and @entity417 in 33% of @entity1 . There were two partial responses (2/24, 8%) and 11 @entity1 (46%) achieved @entity66 ( @entity66 ). The 6-month progression-free rate for @entity1 with @entity66 was 30%. Of the seventeen @entity1 with progressive disease at registration, one had a PR and eight had @entity66 . The overall median survival time for all 24 @entity1 was 10.0 months (90% CI=5.2, 17.4 months). The 12-month survival rate was 39%, with 90% CI=(0.21, 0.58). Nine @entity1 are still alive with survival times ranging from 3.8 to 24.2 months, at a median follow-up time of 11.9 months. CONCLUSION: @entity41329 analog ( @entity53753 ) is well tolerated and has modest antitumor activity in @entity1 with advanced @entity1358 .

title: A phase II study of XXXX analog ( @entity53753 ) in metastatic @entity1358 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell cancer', 'RCC']

entities_list: @entity41329 :: ('MESH:C053339', 'Chemical') :: ['Rebeccamycin']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

answer: @entity41329 :: (MESH:C053339,Chemical) :: ['rebeccamycin']


abstract: Twenty-seven @entity1 with @entity150 were treated at the Glasgow Institute of Radiotherapeutics as part of a national hyperbaric @entity26 trial. These @entity1 were treated on a 4 MeV linear accelerator either in air or in 3 atm, absolute, of @entity26 , by random selection. Of these @entity1 , one-third were found to have high-dose effects to an extent which necessitated surgery. No association was found between the incidence of high-dose effects and treatment in air or hyperbaric @entity26 . The treatment protocol used in all cases was to give an intended modal @entity5 dose of 6000 rad in 24 fractions in approximately 5 weeks. As all @entity1 had received the same modal dose, there was no apparent reason why some had developed high-dose effects. However, on the basis of a Cumulative Radiation Effect (CRE) analysis of the treatment regimes given, a close correlation was found between the maximum CRE achieved and the occurrence of high-dose effects. Above a threshold level of 1910 reu in the maximum CRE achieved, there was a high incidence and rapid onset of high-dose effects. The reasons for the occurrence of the exceptionally high CRE values found in some @entity1 are discussed. From a review of clinical results of bladder treatments, it is apparent that at a CRE level of 1910 reu, the @entity5 control rate is still increasing with CRE. It is proposed that by choosing the dose given on any treatment schedule to keep the maximum value of the CRE achieved just below 1910 reu, the greatest probability of cure would be obtained with minimum complication rate.

title: High-dose effects in the treatment of XXXX under air and hyperbaric @entity26 conditions.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['carcinoma of the bladder']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

answer: @entity150 :: (MESH:D001749,Disease) :: ['carcinoma of the bladder']


abstract: In 1950, Hensel and Zotterman reported cooling-induced desensitization of cold receptors by extracellular discharge recordings of cold fibers. Since then, however, its intracellular mechanism has remained unresolved. We studied @entity4746 -induced desensitization of cold/ @entity4746 receptors ( @entity28093 , transient receptor potential M8) expressed in HEK cells. @entity28093 desensitization depended on extracellular @entity141 ions, indicating that @entity141 influx-induced [ @entity141 ]i elevation caused the desensitization. We studied whether @entity141 -dependent kinase, @entity6164 , mediated @entity28093 desensitization. @entity4515 , a @entity6164 activator, desensitized @entity28093 . Inhibitor of @entity141 -dependent @entity6164 isozymes specifically abolished @entity4515 -induced @entity28093 desensitization. @entity4515 similarly desensitized wild type @entity28093 and mutant @entity28093 , in which @entity563 or @entity1889 residues in some putative @entity6164 phosphorylation sites were replaced by @entity493 . @entity4515 treatment did not induce internalization of @entity28093 . As the basis of cooling-induced desensitization of cold receptors, we conclude that cooling-activated @entity28093 causes @entity141 -dependent @entity6164 isozymes to desensitize @entity28093 itself.

title: @entity141 -dependent XXXX activation mediates @entity4746 -induced desensitization of transient receptor potential M8.

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine']

entities_list: @entity1889 :: ('CHEBI:26986', 'Chemical') :: ['threonine']

entities_list: @entity493 :: ('CHEBI:16449', 'Chemical') :: ['alanine']

answer: @entity6164 :: (MESH:C566847,Disease) :: ['PKC']


abstract: The purpose of this study was to evaluate the efficacy and tolerance of a combination of @entity2600 , @entity901 , and @entity1487 ( @entity1487 )/ @entity4181 in advanced @entity14 (ACC). Twenty-six consecutive @entity1 with ACC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of @entity901 (120 mg/m2 intravenously [i.v.] for 2 hours) on day 1, @entity2600 (250 mg/m2 i.v. for 90 minutes) on day 1, and @entity1487 (2600 mg/m2 plus @entity4181 500 mg/m2 i.v. in a 24-hour infusion) on day 1 and 15, every 4 weeks. Five of the @entity1 (19.2%) had shown previous chemoresistance. One hundred sixty-two cycles were administered (median, 6; range, 3-13 cycles). All @entity1 were evaluated for @entity137 ; 23 were evaluable for response. According to intention-to-treat, the overall response rate was 69.2% (18 @entity1 ; 95% CI: 48.2%-85.7%), including 3 complete remissions (11.5%). Four additional @entity1 (15.3%) had stable disease, and only 1 (3.8%) progressed. Major @entity137 were @entity1398 and @entity294 . Grade 3 @entity1398 occurred in 9 @entity1 (34.6%), and grade 4 occurred in 1 @entity1 (3.8%). Grade 3 @entity294 occurred in 8 @entity1 (30.7%) and grade 4 in 1 @entity1 (3.8%). Other @entity137 were mild. After a median follow-up of 15.5 months, the median progression-free survival was 14 months. Seventeen @entity1 (65.4%) are still alive, and the median overall survival has not been reached yet. This combination of @entity2600 , @entity901 , and @entity1487 / @entity4181 is fairly well tolerated and shows promising activity in ACC. This treatment merits further comparison with other combination regimens.

title: @entity2600 , @entity901 , and XXXX / @entity4181 combination chemotherapy in advanced @entity14 : a phase II study.

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity1487 :: (MESH:D005472,Chemical) :: ['5-fluorouracil']


abstract: BACKGROUND: Leucocyte recruitment is a key feature in ischaemia-reperfusion (I/R)-triggered tissue injury. However, the mechanisms underlying leucocyte-endothelium interactions in the large bowel remain elusive because of a previous lack of models to examine the colonic microcirculation. The aim of this study was to develop and validate a novel method for studying reperfusion-induced leucocyte-endothelium interactions in the colon. METHODS: The superior mesenteric artery was occluded for 30 min in male C57/Bl6 @entity19 and leucocyte responses were analysed in colonic venules after 30-240 min of reperfusion. Analysis of leucocyte rolling and adhesion in colonic venules was made possible by an inverted approach using intravital fluorescence microscopy. RESULTS: Thirty minutes of ischaemia and 120 min of reperfusion induced the strongest and most reproducible increase in leucocyte rolling and adhesion. This was associated with a significant increase in colonic levels of @entity1234 ( @entity1865 ). Administration of @entity208 and @entity224 dismutase reduced I/R-induced leucocyte responses in a dose-dependent manner. Pretreatment with @entity208 attenuated the tissue content @entity1865 in the colon by more than 60 per cent. CONCLUSION: A new method for examining I/R-induced leucocyte responses in the colonic microcirculation is described. @entity26 free radicals play an important role in triggering leucocyte rolling and adhesion in colonic venules.

title: @entity208 and XXXX dismutase protect against leucocyte-endothelium interactions in a novel model of colonic ischaemia-reperfusion.

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['Oxygen']

entities_list: @entity208 :: ('MESH:D000493', 'Chemical') :: ['allopurinol']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']

answer: @entity224 :: (MESH:D013481,Chemical) :: ['superoxide']


abstract: PURPOSE: To analyze adherence to follow-up over 5 years in @entity1 treated with intravitreal ranibizumab for exudative @entity1020 ( @entity1020 ) in a tertiary health care center. To investigate factors associated with failure to continue follow-up. METHODS: Retrospective chart review of all consecutive @entity1 with exudative @entity1020 , who received their first intravitreal ranibizumab injection at the @entity8818  teil Intercommunal University Hospital Eye Clinic between October 1, 2006 and March 31, 2007. @entity1 clinical characteristics at baseline and at the last follow-up visit were recorded. Distance from home to hospital was measured for each @entity1 . A multiple-choice telephone survey was conducted for @entity1 lost to follow-up to determine the main reasons for failure to continue follow-up. RESULTS: Two hundred and one @entity1 were included. The rate of loss to follow-up over the 5-year period was 57% (115/201). Fifty-eight @entity1 lost to follow-up completed the questionnaire. The main reasons reported by @entity1 for follow-up discontinuation were long distance from home to hospital (51.7%, 30/58), subjective dissatisfaction with the benefits of intravitreal injections (34.5%, 20/58), and the excessive burden of periodic follow-up visits (24.1%, 14/58). Three factors were significantly associated with follow-up discontinuation: high age at baseline (82.2 vs. 76.5 years, P<0.001), poor best-corrected visual acuity (BCVA) at baseline (42.5 vs. 51.0 letters, P=0.020), and long distance from home to hospital (132 vs. 17.1km, P<0.001). CONCLUSION: In this study, adherence to follow-up over 5 years was poor. Age and BCVA at baseline and distance from home to hospital were independently associated with long-term adherence.

title: Ranibizumab for exudative XXXX : A five year study of adherence to follow-up in a real-life setting.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['AMD', 'age-related macular degeneration']

answer: @entity1020 :: (MESH:D008268,Disease) :: ['age-related macular degeneration']


abstract: OBJECTIVE: This study aimed to determine factors associated with hospitalization and decisions to prescribe psychotropic medication for @entity1 with @entity4225 seeking care at @entity146 . METHODS: A total of 11,578 consecutive visits were reviewed over a four-year period at a @entity146 emergency service in a tertiary hospital in Spain. Some @entity1 were repeat visitors. Data collected included sociodemographic, clinical, social, and therapeutic information and the Severity of @entity146 ( @entity3507 ) score. RESULTS: @entity4225 was the diagnosis in 1,032 of the visits (9%) to the emergency department, which corresponded to 540 individuals. Of these visits, 11% required hospitalization. Multivariate statistical logistic regression analysis showed that the decision to hospitalize was associated with risk of suicide, danger to others, severity of symptoms, difficulty with self-care, and noncompliance with treatment. The decision to prescribe @entity1245 was related to male sex, @entity148 as the reason for seeking care, little difficulty with self-care, few medical or drug problems, and housing instability. Factors related to the prescription of antipsychotics were male sex, risk of endangering others, and @entity716 as the reason for the visit. Factors associated with the prescription of antidepressants were @entity308 as the reason for seeking help and little premorbid dysfunction. CONCLUSIONS: @entity1 with @entity4225 had greater clinical severity, but the percentage of hospitalizations was lower than for @entity1 without the disorder. Although a @entity146 emergency service is not the ideal setting to initiate pharmacotherapy, in practice, psychiatrists often prescribe medications in this setting. The @entity3507 was a good tool to assess the severity of illness of these @entity1 .

title: Hospitalization and pharmacotherapy for XXXX in a @entity146 emergency service.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity4225 :: ('MESH:D001883', 'Disease') :: ['borderline personality disorder', 'Borderline personality disorder']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['Psychiatric Illness', 'psychiatric', 'psychiatric emergency units']

entities_list: @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepines']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychosis']

answer: @entity4225 :: (MESH:D001883,Disease) :: ['borderline personality disorder']


abstract: The impact of isoosmolar versus low-osmolar contrast media (CM) administration on contrast-induced @entity810 (CI-AKI) and extended @entity8 (ERD) is unclear. We retrospectively examined incidences of CI-AKI and ERD in @entity1 who received @entity7568 (isoosmolar) versus @entity6111 (low-osmolar) during angiography for cardiac indications. Of 713 @entity1 , 560 (cohort A), 190 (cohort B), and 172 (cohort C) had serum @entity1011 monitored at 3 days, 30 days, and 6 months after angiography, respectively. 18% of cohort A developed CI-AKI, which was more common with @entity7568 than @entity6111 (22% versus 13%, P = 0.006). However, @entity1 given @entity7568 were older with lower baseline estimated glomerular filtration rates (eGFR). On multivariate analysis, independent associations with higher CI-AKI risk include age >65 years, female gender, @entity712 , ST-elevation @entity583 , @entity2333 , and @entity3124 , but not CM type, higher CM load, or eGFR < 45   mL/ @entity1009 .73   m(2). 32% of cohort B and 34% of cohort C had ERD at 30 days and 6 months, while 44% and 41% of subcohorts had ERD at 90 days and 1 year, respectively. CI-AKI, but not CM type, was associated with medium- and longer-term ERD, with 3-fold higher risk. Advanced age, emergent cardiac conditions, and @entity3124 are stronger predictors of CI-AKI, compared with CM-related factors. CI-AKI predicts longer-term ERD.

title: Extended renal outcomes with use of @entity7568 versus XXXX after coronary angiography.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction']

entities_list: @entity7568 :: ('MESH:C044834', 'Chemical') :: ['iodixanol']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['cardiac failure']

entities_list: @entity3124 :: ('MESH:D016638', 'Disease') :: ['critical illness']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute kidney injury']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity2333 :: ('MESH:D001018', 'Disease') :: ['intra-aortic balloon pump']

answer: @entity6111 :: (MESH:D007472,Chemical) :: ['iohexol']


abstract: OBJECTIVE: To assess the efficacy of @entity2493 as a preventive therapy for @entity10 @entity10895 in a larger population of @entity1 than has previously been studied. BACKGROUND: @entity10 @entity10895 is defined by its sensitivity to @entity3352 . Rarely can @entity1 be fully tapered off @entity3352 without @entity10 recurrence; thus, the risks associated with chronic @entity3352 usage are substantial for these individuals. @entity2493 , a pineal hormone with a similar chemical structure to @entity3352 , has shown efficacy as a preventive agent for @entity10 @entity10895 in isolated case reports. @entity2493 would be a preferential alternative prophylactic treatment to @entity3352 because of its minimal side effect profile. How truly effective @entity2493 is as a preventive for @entity10 @entity10895 is unknown at present and needs further study. METHODS: Retrospective analysis of all International Classification of @entity2794 -3 beta diagnosed @entity10 @entity10895 @entity1 treated with both @entity3352 and @entity2493 at the Geisinger @entity10 Center from July 2011 to January 2014. RESULTS: Eleven @entity1 were treated (9 @entity1 , 2 @entity1 ). Two @entity1 became @entity158 free on @entity2493 , while partial relief was noted in 3 other @entity1 ; thus, they were able to lower their dose of @entity3352 but could not achieve @entity158 freedom with @entity2493 alone. Six @entity1 had no response. @entity2493 dosing needed for response ranged from 3 to 30   mg. In the partial relief responders, @entity3352 dosing decreased by 50% to 75%. CONCLUSION: From this single clinic investigation, only a small percent of subjects with @entity10 @entity10895 (less than 20%) will achieve @entity158 freedom on @entity2493 , thus clearly not matching the effectiveness of @entity3352 . However, the addition of @entity2493 to @entity3352 may allow around 45% of @entity1 to have complete or partial relief of their @entity10 with the subsequent ability to reduce or eliminate their @entity3352 dosage, which may lead to a decrease in medical morbidity over time secondary to less exposure to @entity3352 .

title: How Effective Is @entity2493 as a Preventive Treatment for XXXX Continua? A Clinic-Based Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity2493 :: ('MESH:D008550', 'Chemical') :: ['Melatonin', 'melatonin']

entities_list: @entity2794 :: ('MESH:D020773', 'Disease') :: ['Headache Disorders']

entities_list: @entity3352 :: ('MESH:D007213', 'Chemical') :: ['indomethacin']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['Headache', 'hemicrania', 'Hemicrania', 'headache']

answer: @entity10 :: (MESH:D006261,Disease) :: ['Hemicrania']


abstract: UNASSIGNED: Context-Solid-organ transplant is the treatment of choice for end-stage organ failure and requires a transition from management of a life-threatening condition to a @entity102 . Despite research focusing on quality of life after transplant, there is a gap addressing the role of managing a @entity102 focusing on vulnerability and impact on family. Objective-Identify @entity1 and family patterns of adaptation among kidney and liver transplant recipients in regard to (1) vulnerability, (2) impact of illness on the family, (3) family functioning, and (4) quality of life (parent and @entity1 report). Design-Cross-sectional study enrolling @entity1 5 to 18 years old and their parent at a single time point after kidney or liver transplant. Validated self-report tools were completed. Results-In all, 47 @entity1 (24 kidney and 23 liver) were recruited. Mean age at transplant was 4.0 (kidney) and 2.1 (liver) years. Mean age at report was 12.1 (kidney) and 7.1 (liver) years. @entity1 vulnerability correlated negatively with (1) family impact in the kidney (P < .05) and liver (P < .05) transplant groups, (2) PedsQL subscales including Parent Emotional (P< .05), Parent Social (P< .01), Parent Psychosocial (P < .01), Parent Physical (P < .05), Parent School (P < .05), and @entity1 Social (P < .01) in the kidney transplant group, (3) PedsQL Parent Emotional subscale (P< .01) in the liver transplant group, and (4) Functional status (P < .01) in the liver transplant group. Conclusions- @entity1 vulnerability provides insight into quality of life and the impact of illness on the family and family functioning.

title: Vulnerability and XXXX management in pediatric kidney and liver transplant recipients.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Child', 'children', 'patient', 'child']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic illness']

answer: @entity102 :: (MESH:D002908,Disease) :: ['chronic illness']


abstract: UNASSIGNED: Objective. To compare T2(   ) value of healthy and diseased @entity924 ( @entity924 ) with a recently introduced three-dimensional ultrashort echo time (3D-UTE) sequence and analyze the correlation between T2(   ) value and clinical scores. Methods. Ten @entity1 with symptomatic Achilles tendon and ten healthy volunteers were investigated with 3D-UTE sequence on a 3T magnetic resonance (MR) scanner. T2(   ) values of four regions in @entity924 were calculated. The clinical outcomes of @entity1 were evaluated according to the American Orthopaedic Foot and Ankle Society (AOFAS) score and Achilles @entity397 Score (ATRS). An independent sample t-test was used to compare the differences of T2(   ) value and clinical scores between two groups. The Pearson correlation coefficient between clinical scores and T2(   ) values was assessed. Results. The T2(   ) values of Achilles tendon were statistically significantly different between @entity1 and volunteers. The Pearson correlation coefficients between T2(   ) and AOFAS or ATRS scores of @entity1 were r = -0.733 and r = -0.634, respectively. Conclusion. The variability of T2(   ) in healthy and pathologic @entity924 can be quantified by @entity9212 (   ). T2(   ) may be a promising marker to detect and diagnose @entity924 . @entity9212 (   ) could give a precise guidance to clinical outcome.

title: XXXX (   ) Analysis of Diseased and Healthy Achilles Tendons and Correlation with Clinical Score: An In Vivo Preliminary Study.

entities_list: @entity924 :: ('MESH:D052256', 'Disease') :: ['AT tendinopathy', 'Achilles tendons', 'AT']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['Tendon Rupture']

answer: @entity9212 :: (MESH:C535434,Disease) :: ['UTE-T2']


abstract: BACKGROUND _ OBJECTIVE: Induction chemotherapy plus concurrent radiochemotherapy may prolong disease-free and overall survival of advanced @entity189 ( @entity189 ) @entity1 . This study was to compare the long-term efficacy of induction chemotherapy plus concurrent radiochemotherapy and radiotherapy alone on advanced @entity189 . METHODS: Clinical data of 535 advanced @entity189 @entity1 , treated in @entity5 Center of Sun Yat-sen University from Jan. 1997 to Dec. 1998, were analyzed. Of the 535 @entity1 , 75 were treated with 3-5 cycles of induction and concomitant chemotherapy of PF regimen ( @entity900 combined @entity1487 ) plus radiotherapy, 460 were treated with radiotherapy alone. The survival statuses of the 2 groups were compared. Prognostic factors were analyzed by Cox regression analysis. Cumulative survival rate was analyzed by Kaplan-Meier method. RESULTS: The 5-year overall and disease-free survival rates were significantly higher in radiochemotherapy group than in radiotherapy group (78.15% vs. 55.27%, 71.55% vs. 48.99%, P<0.05). For the @entity1 with @entity5 , the median overall and disease-free survival term were significantly longer in radiochemotherapy group than in radiotherapy group (94.5 months vs. 85.1 months, 89.5 months vs. 82.9 months, P<0.05). For the @entity1 with stage IVa @entity5 , the same results were obtained (82.4 months vs. 44.4 months, 69.6 months vs. 40.3 months, P<0.05). Cox regression analysis showed that clinical stage and chemotherapy were dependent prognostic factors of advanced @entity189 . CONCLUSION: Induction chemotherapy plus concurrent radiochemotherapy could prolong the survival of @entity1 with advanced @entity189 .

title: [Long-term efficacy of induction chemotherapy plus concurrent radiochemotherapy on advanced XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III tumors', 'Cancer', 'tumors']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['nasopharyngeal carcinoma', 'NPC']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']

answer: @entity189 :: (MESH:D002277,Disease) :: ['nasopharyngeal carcinoma']


abstract: OBJECTIVES: We performed 52 peripheral nerve stimulation procedures since 1991. In addition to 48 @entity1 with @entity6866 II, 4 @entity1 with phantom-limb @entity158 were treated. Incomplete or complete lesion of the stimulated peripheral nerves was determined in all @entity1 . Surgically treatment failed in all cases. All @entity1 had been given extensive conservative @entity158 therapy. MATERIAL AND METHOD: The aim was to define a standardised method, which would be as objective as possible, to verify the success of treatment, by measuring the @entity158 assessment, the subjective intensity of @entity158 and the subjective perception of @entity158 . Long-term follow-up was arranged in addition to determine social and occupational re-integration. The implantation of the stimulating electrode, proximal to the lesion, was performed after microsurgical neurolysis of the peripheral nerves. The @entity1 carried out a stimulation trial after the operation. At the conclusion of the trial stimulation phase, a stimulator unit was permanently implanted in 47 cases, with a marked @entity158 . Only in 5 cases, the success of the trial stimulation was unsatisfactory. RESULTS: After implanting the stimulator unit an average @entity158 of 10% was achieved by the 47 @entity1 fitted with a permanent implant. 43 @entity1 have used the permanent stimulator implants with lasting, excellent to good success. The stimulator system was removed in only 4 cases, due to the need for stimulation having passed, or due to a lack of lasting success with stimulation. CONCLUSION: Neurostimulation of peripheral nerves should be considered as an established concept to treat surgically failed @entity1897 .

title: [Peripheral nerve stimulation for @entity158 relief in @entity6866 II and phantom-limb XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral nerve lesions']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain-related disability', 'reduction in pain', 'pain']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: BACKGROUND: The @entity1162 are important substrates of malignant @entity943 . The feasibility of mapping and ablation of @entity943 in these conditions has not been reported. METHODS AND RESULTS: Seven @entity1 (4 @entity1 ; age, 38+/-7 years; 4 with long-QT and 3 with @entity1789 ) with episodes of @entity2224 or polymorphic @entity1165 and frequent isolated or repetitive premature beats were studied. These premature beats were observed to trigger @entity943 and were localized by mapping the earliest endocardial activity. In 4 @entity1 , premature beats originated from the peripheral right (1 Brugada) or left (3 long-QT) Purkinje conducting system and were associated with variable Purkinje-to-muscle conduction times (30 to 110 ms). In the remaining 3 @entity1 , premature beats originated from the right ventricular outflow tract, being 25 to 40 ms ahead of the QRS. The accuracy of mapping was confirmed by acute elimination of premature beats after 12+/-6 minutes of radiofrequency applications. During a follow-up of 17+/-17 months using ambulatory monitoring and defibrillator memory interrogation, no @entity1 had recurrence of symptomatic @entity943 but 1 had persistent premature beats. CONCLUSIONS: Triggers from the Purkinje arborization or the right ventricular outflow tract have a crucial role in initiating @entity2224 associated with the @entity1162 . These can be eliminated by focal radiofrequency ablation.

title: Mapping and ablation of @entity2224 associated with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity1789 :: ('MESH:D053840', 'Disease') :: ['Brugada syndrome']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['long-QT and Brugada syndromes']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmia', 'ventricular arrhythmias']

answer: @entity1162 :: (MESH:D008133,Disease) :: ['long-QT and Brugada syndromes']


abstract: @entity2895 which occur with intracranial @entity808 are very rare. CASE: A 29-year-old right-handed female was admitted to the Department of Neurosurgery, Hokkaido University School of Medicine on @entity24904 , 1975. Eight months before admission, the @entity1 complained of @entity892 and one month later, noticed decreasing of right visual acuity. Four months before admission, right-sided @entity1736 occurred and she noticed right temporal @entity227 . Two weeks before admission she became aware of @entity5768 of right side. On admission, the general examination and vital signs were normal. The neurological examination revealed right optic nerve @entity194 , @entity2895 and slight decreasing of right corneal reflex. Radiological examination revealed @entity66 in the middle fossa. On Sept. 19, 1975, a right frontotemporal craniotomy was performed and a large dura-covered @entity5 was found. It was found to extend from the middle fossa to the superior orbital fissure and attached to the anterior wall of the middle fossa. The @entity5 expanded into the interdual space and tightly attached to the dura mater. Histological examination of the @entity5 revealed @entity808 . Reports on cases with @entity808 were reviewed and the origin of the @entity5 was discussed. It was presumed that the origin of the @entity5 in this case was the dural branch of the trigeminal nerve in the middle fossa.

title: [Middle fossa XXXX with @entity5768 and @entity2895 (author's transl)].

entities_list: @entity808 :: ('MESH:D009442', 'Disease') :: ['typical neurinoma', 'middle fossa neurinoma', 'neurinoma']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ["visual field's defect"]

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['extracerebral mass lesion']

entities_list: @entity5768 :: ('MESH:D005094', 'Disease') :: ['proptosis']

entities_list: @entity2895 :: ('MESH:D015840', 'Disease') :: ['Proptosis and oculomotor palsy', 'right oculomotor palsy']

entities_list: @entity892 :: ('MESH:D004172', 'Disease') :: ['double vision']

answer: @entity808 :: (MESH:D009442,Disease) :: ['neurinoma']


abstract: PURPOSE: @entity5721 ( @entity5721 ) is a common early complication after lung transplantation. The purpose of this study was to compare ultrashort echo-time (UTE) sequences in magnetic resonance imaging (MRI) with a microcomputed tomography (micro-CT) reference standard for detection of @entity5721 injury in a lung transplantation @entity19 model. MATERIALS AND METHODS: Six @entity19 (C57BL/6) underwent orthotopic lung transplantation using donor grafts that were exposed to 6-hour cold @entity63 . Imaging was performed within 24 hours after the transplantation with high-resolution micro-CT (tube voltage, 50 kV; current, 500 mA; @entity3775 filter, 0.5 mm; voxel size, 35   35   35  m  ) and small-animal MRI at 4.7 T with a linearly polarized whole-body @entity19 coil. The imaging protocol comprised radial 3-dimensional UTE sequences with different echo times (repetition time, 8 milliseconds; echo time, 50/75/100/500/1500/3000/4000/5000  s; voxel size, 350   350   350  m  ). Images were assessed visually and through calculation of contrast-to-noise ratio (CNR) values. Calculated S0 values and T2* transverse relaxation times (MRI) of lung parenchyma were compared with Hounsfield unit (HU) density in micro-CT images. Receiver operating characteristic curves and area under the curve values were calculated for comparison of diagnostic power. All samples underwent a histologic examination. RESULTS: The results of both UTE MRI and micro-CT showed an excellent depiction of @entity358 due to @entity5721 injury, with MRI exhibiting a significantly higher CNR (mean [SD] CNR MRI, 19.7 [8.0]; mean [SD] CNR micro-CT, 10.3 [2.5]; P < 0.001). Measured parametrical values were as follows: mean (SD) HU, -416 (120); mean (SD) S0 value, 1655 (440); mean (SD) T2*, 895 (870)  s for the non-transplanted right lung and mean (SD) HU, 29 (35); mean (SD) S0 value, 2310 (300); and mean (SD) T2*, 4550 (3230)  s for the transplanted left lung. Slight infiltration could be better discriminated with micro-CT, whereas, in strong infiltration, a better contrast was provided by UTE MRI. The area under the curve values resulting from the receiver operating characteristic curve analysis were 0.99 for HU density, 0.89 for S   , 0.96 for T2*, and 0.98 for the combination of S    and T2*. CONCLUSIONS: Results show that MRI of the lung has a similar diagnostic power compared with that of micro-CT regarding the detection of @entity5721 injury after experimental lung transplantation. Both modalities provide complementary information in the assessment of dense and slight infiltration in the early phase after lung transplantation. Therefore, UTE MRI seems to be a promising addition to computed tomographic imaging in the assessment of @entity5721 injury after lung transplantation.

title: Assessing lung transplantation XXXX -reperfusion injury by microcomputed tomography and ultrashort echo-time magnetic resonance imaging in a @entity19 model.

entities_list: @entity3775 :: ('MESH:D000535', 'Chemical') :: ['aluminum']

entities_list: @entity5721 :: ('MESH:D015427', 'Disease') :: ['I/R', 'Ischemia-reperfusion injury']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary infiltration']

answer: @entity63 :: (MESH:D007511,Disease) :: ['ischemia']


abstract: BACKGROUND: @entity2806 -reperfusion (I-R) injury is one of the primary causes of @entity385 . Ischemic postconditioning (iPoCo) is evolving as an important adaptive technique to contain I-R injury. Some recent studies have shown neuroprotective effects of iPoCo. However, the neuroprotective mechanism of iPoCo is not clear. So, the present study has been undertaken to investigate the possible role of @entity11936 , a selective class III histone deacetylase (HDAC) inhibitor in the neuroprotective mechanism of iPoCo in @entity19 . MATERIAL AND METHODS: Bilateral carotid artery occlusion (BCAO) for 12  min followed by reperfusion for 24  h was used to produce I-R-induced @entity131 in Swiss albino @entity19 . iPoCo involving three episodes of 10-s carotid artery occlusion and reperfusion instituted immediately after BCAO just before prolonged reperfusion of 24  h. @entity385 size was measured using @entity5045 staining. Memory was evaluated using a Morris water maze test. Rotarod test, inclined beam-walking test, and neurologic severity score (NSS) were used to assess motor incoordination. @entity934 esterase levels, brain @entity4466 reactive species (TBARS), and @entity2041 level were also estimated. RESULTS: BCAO for 12  min followed by reperfusion for 24  h produced a significant rise in @entity385 size and NSS along with @entity73 and biochemical alteration (  - @entity934 esterase,    @entity2041 , and   -TBARS). iPoCo, involving three episodes of 10-s carotid artery occlusion with intermittent reperfusion of 10  s applied just after ischemic insult of 12  min produced a significant decrease in @entity385 size and NSS along with the reversal of I-R-induced @entity73 . iPoCo-induced neuroprotective effects were significantly abolished by pretreatment with selective @entity14075 (class III HDAC) blocker @entity11936 (10  mg/kg intraperitoneal). CONCLUSIONS: It may be concluded that the neuroprotective effect of iPoCo probably involves activation of @entity14075 (class III HDAC) enzyme.

title: Pharmacologic investigations on the role of XXXX in neuroprotective mechanism of postconditioning in @entity19 .

entities_list: @entity5045 :: ('MESH:C009591', 'Chemical') :: ['triphenyltetrazolium chloride']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['cerebral injury']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['Cerebral ischemia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impairment of memory and motor coordination']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine', 'Acetylcholine']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity4466 :: ('MESH:C029684', 'Chemical') :: ['thiobarbituric acid']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke', 'cerebral infarct', 'Cerebral infarct']

answer: @entity14075 :: (93759(Tax:10090),Gene) :: ['Sirt-1']


abstract: BACKGROUND: In 1999, five randomized studies demonstrated that chemoradiation with @entity900 and low-dose rate (LDR) brachytherapy has a benefit in locally advanced @entity5 and for surgically treated @entity1 in high-risk situations. We evaluated the safety and efficacy of concomitant chemoradiation with @entity900 and @entity1168 ( @entity1168 ) brachytherapy in @entity1 with @entity5 . @entity1 AND METHODS: 27 @entity1 were included in our phase-II trial: 13 locally advanced cases (group A) and 14 adjuvant-therapy @entity1 in high-risk situations (group B). A definitive radiotherapy was performed with 25 fractions of external beam therapy (1.8 Gy per fraction/middle shielded after eleven fractions). Brachytherapy was delivered at @entity1168 schedules with 7 Gy in point A per fraction (total dose 35 Gy) in FIGO Stages IIB-IIIB. The total dose of external and brachytherapy was 70 Gy in point A and 52-54 Gy in point B. All @entity1 in stage @entity3480 were treated without brachytherapy. Adjuvant radiotherapy was performed with external beam radiotherapy of the pelvis with 1.8 Gy single-dose up to 50.4 Gy. Brachytherapy was delivered at @entity1168 schedules with two fractions of 5 Gy only in @entity1 with @entity5 -positive margins or @entity5 involvement of the @entity8376 . The chemotherapeutic treatment schedule provided six courses of @entity900 40 mg/m2 weekly recommended in the randomized studies GOG-120 and -123. RESULTS: A total of 18/27 @entity1 (66.7%) completed all six courses of chemotherapy. Discontinuation of radiotherapy due to therapy-related morbidity was not necessary in the whole study group. G3 @entity1431 (29.6%) was the only relevant acute @entity137 . There were no differences in @entity137 between group A and B. Serious late morbidity occurred in 2/27 @entity1 (7.4%). 12/13 @entity1 (92.3%) with @entity5 showed a complete response (CR). 13/14 adjuvant cases (92.8%) are free of recurrence (median follow up: 19.1 months). CONCLUSION: Concomitant chemoradiation with @entity900 40 mg/m2 weekly x 6 using @entity1168 brachytherapy represents a promising treatment of @entity5 with an acceptable @entity137 .

title: @entity5 with @entity900 and XXXX brachytherapy combined with external beam radiotherapy. Results of a phase-II study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer', 'IIB-IVA cervical cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia']

entities_list: @entity8376 :: ('MESH:D014625', 'Disease') :: ['upper vagina']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['high-dose rate', 'HDR']

answer: @entity1168 :: (MESH:D001919,Disease) :: ['high-dose rate']


abstract: UNASSIGNED: Purpose: To characterize dose and response for intraocular pressure (IOP) reduction and incidence of @entity450 using a model-based meta-analysis of IOP-lowering monotherapy studies to evaluate new ocular antihypertensive therapies for @entity726 . Methods: Published randomized controlled trials, regulatory documents, and sponsor reports of IOP-lowering monotherapies were used to develop dose-response models to characterize efficacy (IOP change from baseline) and safety (incidence of @entity450 ) profiles. Results: The meta-analysis for efficacy included 31 trials with 6,516 @entity1 receiving bimatoprost, latanoprost, travoprost, @entity6839 , or placebo. Estimated IOP reduction with placebo was -2.01   mmHg. @entity2790 was similar among the @entity3009 analogs (estimate, -6.27   mmHg; baseline, 25   mmHg). Estimated median effective IOP-lowering dose (ED50) was 0.002%, 0.00098%, and 0.00063% daily with bimatoprost, latanoprost, and travoprost, respectively. The @entity450 (safety) analysis included 25 trials with 6,244 @entity1 . Typical maximal estimated difference between drug and placebo was 43%, and estimated ED50 of 0.011%, 0.014%, and 0.0015% daily for bimatoprost, latanoprost, and travoprost, respectively. Latanoprost treatment was predicted to incur the lowest rate of @entity450 of the @entity2918 , for equivalent IOP reduction. Conclusions: Model-based meta-analyses for IOP reduction and incidence of @entity450 among prostaglandin analogs are well described by maximal efficacy models and can provide a useful methodology for evaluating @entity726 therapies.

title: A Model-Based Dose-Response Meta-Analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['hyperemia']

entities_list: @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin']

entities_list: @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostaglandins']

entities_list: @entity2790 :: ('MESH:D009798', 'Disease') :: ['Maximal IOP reduction']

answer: @entity726 :: (MESH:D005901,Disease) :: ['Glaucoma']


abstract: STUDY OBJECTIVE: Demonstrate improved efficiency of initial and subsequent in-hospital care following @entity341 ( @entity341 ) physician-initiated primary angioplasty (1 PCI). METHODS: An observational study was undertaken in ST-elevation @entity583 @entity1 presenting to a community hospital @entity341 . Outcomes of @entity1 who received @entity341 physician-directed 1 PCI were compared with @entity1 previously treated by a mix of @entity341 physician and cardiologist co-determined thrombolysis or 1 PCI. A process improvement initiative supported the change to @entity341 -directed 1 PCI. RESULTS: The study included 287 eligible acute reperfusion @entity1 . Median door-to-balloon time (MDBT) improved from 88 minutes (95% CI, 80 96) to 61 minutes (95% CI, 57 70; p < 0.0001). Necessary subsequent in-hospital interventions (NSI) occurred in 70 of 107 (65.4%; 95% CI, 55.6 74.4%) thrombolytic @entity1 , versus 3 of 99 (3.0%; 95% CI, 0.6 8.6%) 1 PCI @entity1 at baseline, and 1 of 81 (1.2%; 95% CI, 0.0 6.7%) 1 PCI @entity1 after process change. Median length of stay (LOS) decreased from 4 days for thrombolytic @entity1 and 3 days for 1 PCI @entity1 at baseline, to 2 days for 1 PCI after adopting the improved process (p < 0.0001). Effectiveness outcomes demonstrating improvement included discharge on beta-blocker (p = 0.0039), @entity1289 inhibitor (p < 0.0001) and anti-lipid therapy (p = 0.0039), with favorable trends in survival to discharge, and 30-day major adverse @entity299 (MACE). CONCLUSIONS: Conversion to @entity341 physician-initiated 1 PCI for ST-elevation @entity583 significantly improved efficiency of care as measured by MDBT, NSI and LOS. Effectiveness measures, including survival to discharge, discharge medications and 30-day MACE, demonstrated improvement or favorable trends.

title: Improved efficiency in acute @entity583 care through commitment to XXXX -initiated primary PCI.

entities_list: @entity1289 :: ('1636', 'Gene') :: ['angiotensin-converting-enzyme']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity341 :: (MESH:D004630,Disease) :: ['emergency department']


abstract: INTRODUCTION: Revascularization of occlusion of the femoropopliteal region in @entity1 with @entity4218 ( @entity4218 ) may be performed following the standard surgical approach using bypass with the saphenous vein graft (FP bypass). Unfortunately, up to 40% of these @entity1 do not have a suitable saphenous vein. In these @entity1 , revascularization may be performed surgically using bypass with prosthesis, allograft vein or by interventional radiological methods. An endovascular alternative is represented by subintimal recanalization (SIR). MATERIAL AND METHODS: Our prospective analysis evaluated mid-term results of revascularization using FP bypass or SIR in @entity1 with occlusion of the femoropopliteal region and @entity4218 . Our aim was to answer the question whether SIR can fully replace FP bypass in certain indications. From January 2010 to December 2012, 59 revascularizations of the @entity4218 (Rutherford 5-6) with comparable SFA occlusion were performed. We monitored the immediate postoperative course, technical and clinical success and the process of healing of the defect. RESULTS: Healing of the defect was achieved in 78.6% of @entity1 with FP bypass using the saphenous vein, in 62.5% of @entity1 with FP bypass using prosthesis and in 64.9% of @entity1 with SIR (P=0.578). When comparing the bypass group, which was subdivided into a group with revascularization using autologous vein and a group with revascularization using ePTFE prosthesis, with the SIR group, primary patency was evaluated. The results for vein 78.0% after 6, 12, 24 and 36 months, for prosthesis 74.5%, 55%, 55% after 6, 12 and 24 months, and for the SIR group 78%, 60%, 51.3% and 50.7% after 6,12,24 and 36 months. When comparing the results of the groups, no statistically significant difference was found (P =0.625). CONCLUSION: As expected, the most successful method of choice is revascularization by FPB using the saphenous vein. SIR and FP bypass using prosthesis had similar results with respect to healing of the defects.

title: [Comparison between femoropopliteal bypass and subintimal recanalization in the treatment of XXXX ].

entities_list: @entity4218 :: ('MESH:D017880', 'Disease') :: ['critical limb ischaemia', 'CLI']

answer: @entity4218 :: (MESH:D017880,Disease) :: ['critical limb ischaemia']


abstract: UNASSIGNED: Polychlorinated biphenyls (PCBs) are typical persistent organic pollutants that can interfere with multiple organ systems of @entity1 . Previously, we concluded that persistent exposure to low doses of @entity65154 could severely damage the thyroidal structure, dramatically decrease the concentration of serum thyroid hormones and inhibit the pivotal gene expressions such as sodium/iodide symporter (NIS) and thyroglobulin (Tg). To explore the molecular mechanisms of thyrocyte dysfunction induced by 2,3',4,4',5-pentachlorobiphenyl ( @entity65154 ), monolayer cultured @entity1 thyroid epithelial cells (HTECs) were treated with @entity65154 or dimethyl sulfoxide (DMSO) as a control. Our results indicated that relatively higher concentrations of @entity65154 could induce a loss in the viability of HTEC. In cultures with concentrations of @entity65154 from 0.025 to 25 nM, which did not affect cell viability or apoptosis, concentrations of Tg and thyroxine (T4 ) were significantly decreased compared with those in the controls. In addition, mRNA and protein levels of @entity584 were increased significantly in the @entity65154 -treated groups, whereas @entity16389 expression did not show particular variation. Furthermore, exposure to @entity65154 was associated with a significant increase of the protein levels of p- @entity584 and p- @entity16389 , and these effects were blocked by @entity2306 . In contrast, mRNA and protein expression levels of NIS were decreased significantly, and this effect was blocked by @entity2306 . Unlike control cells, a cytoplasmic shift of @entity16389 was observed in the @entity65154 -treated group. Our research suggests that @entity65154 may induce thyrocyte dysfunction through the @entity584 / @entity16389 /NIS signalling pathway, which provides potential new insights for finding interventions to counteract the damage to the @entity1 body caused by PCBs. Copyright    2015 John Wiley _ Sons, Ltd.

title: Molecular mechanisms of XXXX thyrocyte dysfunction induced by low concentrations of polychlorinated biphenyl 118 through the @entity584 / @entity16389 /NIS pathway.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: The clinical and radiologic findings in 19 @entity1 with @entity410 and surgically proved @entity1779 were reviewed to characterize the radiologic features of these lesions. The CT and MR findings were not specific. On CT the @entity7667 can be hypodense with no enhancement and they often have @entity730 . On MR these @entity5 have a wide variety of signals. In five of our cases the @entity5 had a high-intensity signal with a cystlike component on proton density- and T2-weighted images. In five cases the lesion had an inhomogeneously intense signal on proton density-weighted images and high signal intensity on T2-weighted images. The @entity5 had high-intensity signal on both proton density- and T2-weighted images in four @entity1 . Finally, in two cases the MR findings were normal. We recommend MR as the examination of choice for @entity1 with @entity410 because it allows an artifact-free evaluation of the temporal region. However, CT should also be performed in order to recognize @entity730 that may be missed on the MR examination.

title: @entity1779 in @entity1 with XXXX : CT and MR imaging findings.

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['partial complex seizures']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity730 :: ('MESH:D002114', 'Disease') :: ['calcifications']

entities_list: @entity7667 :: ('MESH:D018303', 'Disease') :: ['gangliogliomas']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral gangliogliomas']

answer: @entity410 :: (MESH:D012640,Disease) :: ['partial complex seizures']